Profile
6.43 -0.04(-0.54%)03/06/2026
Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc. (APVO)
| Stock Exchange | United States (NASDAQ) |
| Sector | Healthcare |
| Industry | Biotechnology |
| CEO | Marvin L. White |
| Website | https://www.aptevotherapeutics.com |
| First Price Date | 2016-07-20 |
| Last Price Date | 2026-03-06 |
| Long Description Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company''s preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. | |